Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.

MLA

Vecchi, M., et al. “Oral versus Combination Mesalazine Therapy in Active Ulcerative Colitis: A Double-Blind, Double-Dummy, Randomized Multicentre Study.” Alimentary Pharmacology & Therapeutics, vol. 15, no. 2, Feb. 2001, pp. 251–56. EBSCOhost, https://doi.org/10.1046/j.1365-2036.2001.00913.x.

APA

Vecchi, M., Meucci, G., Gionchetti, P., Beltrami, M., Di Maurizio, P., Beretta, L., Ganio, E., Usai, P., Campieri, M., Fornaciari, G., & De Franchis, R. (2001). Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Alimentary Pharmacology & Therapeutics, 15(2), 251–256. https://doi.org/10.1046/j.1365-2036.2001.00913.x

Chicago

Vecchi, M., G. Meucci, P. Gionchetti, M. Beltrami, P. Di Maurizio, L. Beretta, E. Ganio, et al. 2001. “Oral versus Combination Mesalazine Therapy in Active Ulcerative Colitis: A Double-Blind, Double-Dummy, Randomized Multicentre Study.” Alimentary Pharmacology & Therapeutics 15 (2): 251–56. doi:10.1046/j.1365-2036.2001.00913.x.